HER-2/neu in Lung Cancer
Author Information
Author(s): Fred R. Hirsch, Maria Varella-Garcia, W. A. Franklin, R. Veve, L. Chen, B. Helfrich, C. Zeng, A. Baron, P. A. Bunn Jr.
Primary Institution: University of Colorado Health Sciences Center
Hypothesis
What is the significance of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas?
Conclusion
HER-2/neu overexpression was found in 16% of non-small cell lung carcinomas, but it did not significantly impact survival outcomes.
Supporting Evidence
- HER-2/neu overexpression was observed in 16% of non-small cell lung carcinomas.
- 35% of adenocarcinomas showed positive HER-2/neu expression.
- Statistical analysis showed no significant difference in survival between HER-2/neu positive and negative tumors.
Takeaway
This study looked at a protein called HER-2/neu in lung cancer and found that while some tumors had high levels of it, it didn't seem to help patients live longer.
Methodology
The study used immunohistochemistry and fluorescence in situ hybridization to evaluate HER-2/neu expression in lung cancer samples.
Potential Biases
Potential biases may arise from the selection of tumor samples and the interpretation of immunohistochemistry results.
Limitations
The study's findings may not be generalizable due to the specific patient population and the retrospective nature of the data collection.
Participant Demographics
The study included 238 patients with non-small cell lung cancer, with a median age of 65 years, comprising 39 males and 12 females.
Statistical Information
P-Value
0.86
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website